{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:26:15Z","timestamp":1789475175773,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tecnologico de Monterrey","award":["PhD Scholarship"],"award-info":[{"award-number":["PhD Scholarship"]}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Inovaci\u00f3n","award":["PhD Scholarship CVU number 846934"],"award-info":[{"award-number":["PhD Scholarship CVU number 846934"]}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Inovaci\u00f3n","award":["FOSSIS-272823"],"award-info":[{"award-number":["FOSSIS-272823"]}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Inovaci\u00f3n","award":["FOSSIS-27282"],"award-info":[{"award-number":["FOSSIS-27282"]}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Inovaci\u00f3n","award":["FOSSIS-272823"],"award-info":[{"award-number":["FOSSIS-272823"]}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Inovaci\u00f3n","award":["FOSSIS-272823"],"award-info":[{"award-number":["FOSSIS-272823"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer prognosis is the result of complex interactions between tumor biology, treatment, and host factors. While germline genetic variation is increasingly incorporated into breast cancer risk assessment and therapeutic decision-making, its role in determining prognosis remains incompletely defined. This systematic review and meta-analysis synthesizes available evidence on the association between germline genetic variants and breast cancer outcomes, with a focus on pathway-level effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted in PubMed, Scopus, MEDLINE, Web of Science, and QInsight to identify studies published between January 2000 and June 2024. Published articles that evaluated associations between germline genetic variants and breast cancer prognosis were included. Eligible studies reported time-to-event outcomes, including disease-free survival (DFS), overall survival (OS), and other outcomes. Genes harboring prognostic variants were grouped into functional clusters using STRING. Primary analyses consisted of cluster-based multilevel random-effects meta-analyses, while global outcome-based meta-analyses were conducted as secondary, exploratory analyses. The protocol was registered in PROSPERO (CRD42022308746) and followed PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-four studies encompassing 253,768 women were included. Most participants were of European ancestry, with marked underrepresentation of Hispanic (0.21%) and Black (0.25%) populations. Cluster-based meta-analyses identified six biologically coherent pathways associated with adverse prognosis. The ERBB2\u2013PI3K resistance network showed the strongest association with OS (HR\u2009=\u20093.47; 95% CI: 1.54\u20137.78) and DFS (HR\u2009=\u20091.70; 95% CI: 1.02\u20131.82). Immune-related cytokine pathways were consistently associated with poorer OS (HR\u2009=\u20092.29; 95% CI: 1.04\u20135.04) and DFS (HR\u2009=\u20091.49; 95% CI: 1.20\u20131.85). Germline variation in xenobiotic metabolism genes was significantly associated with OS (HR\u2009=\u20091.65; 95% CI: 1.24\u20132.20), while DNA repair genes were strongly associated with breast cancer\u2013specific mortality (HR\u2009=\u20093.51; 95% CI: 1.80\u20136.85). Exploratory global meta-analyses pooling all variants demonstrated overall directional associations with OS (HR\u2009=\u20092.30) and DFS (HR\u2009=\u20091.49), with substantial heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis show that germline genetic variation influences breast cancer prognosis in a pathway-specific manner. These findings highlight the importance of biologically informed analytic strategies and underscore the need for large, ethnically diverse studies to validate pathway-level germline prognostic markers and support their integration into personalized breast cancer management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15808-7","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:04:08Z","timestamp":1772633048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5526-687X","authenticated-orcid":false,"given":"Ariadna","family":"Guti\u00e9rrez-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-9001","authenticated-orcid":false,"given":"Eric Jonathan","family":"Maciel-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-2287","authenticated-orcid":false,"given":"Nancy","family":"Reynoso-Nover\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-4787","authenticated-orcid":false,"given":"Alejandro","family":"Mohar-Betancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3587-339X","authenticated-orcid":false,"given":"Cynthia","family":"Villarreal-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-4192","authenticated-orcid":false,"given":"Lizbeth","family":"Grimaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-3017","authenticated-orcid":false,"given":"Miguel","family":"Trujillo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-639X","authenticated-orcid":false,"given":"Liliana","family":"G\u00f3mez-Flores-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"15808_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024, CA. Cancer J. Clin., 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"key":"15808_CR2","doi-asserted-by":"publisher","unstructured":"Polyak K. Heterogeneity in breast cancer. J Clin Invest. Oct. 2011;121(10):3786\u20138. https:\/\/doi.org\/10.1172\/JCI60534.","DOI":"10.1172\/JCI60534"},{"key":"15808_CR3","doi-asserted-by":"publisher","unstructured":"Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ, 2009;338(1):b375\u2013b375. https:\/\/doi.org\/10.1136\/bmj.b375.","DOI":"10.1136\/bmj.b375"},{"key":"15808_CR4","doi-asserted-by":"publisher","unstructured":"Moossdorff M, et al. Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. JNCI J Natl Cancer Inst. Dec. 2014;106(12). https:\/\/doi.org\/10.1093\/jnci\/dju288.","DOI":"10.1093\/jnci\/dju288"},{"key":"15808_CR5","doi-asserted-by":"publisher","unstructured":"Moy L, et al. ACR Appropriateness Criteria \u00ae Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. J Am Coll Radiol. May 2017;14(5):S282\u201392. https:\/\/doi.org\/10.1016\/j.jacr.2017.02.009.","DOI":"10.1016\/j.jacr.2017.02.009"},{"key":"15808_CR6","doi-asserted-by":"publisher","unstructured":"Dillek\u00e5s H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med., 2019;8:5574\u20135576. https:\/\/doi.org\/10.1002\/cam4.2474.","DOI":"10.1002\/cam4.2474"},{"key":"15808_CR7","doi-asserted-by":"publisher","unstructured":"Robinson AG, Booth CM, Eisenhauer EA. Disease-free survival as an end-point in the treatment of solid tumours \u2013 Perspectives from clinical trials and clinical practice. Eur J Cancer. Sept. 2014;50(13):2298\u2013302. https:\/\/doi.org\/10.1016\/j.ejca.2014.05.016.","DOI":"10.1016\/j.ejca.2014.05.016"},{"key":"15808_CR8","doi-asserted-by":"publisher","unstructured":"Ajani JA, et al. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. Eur J Cancer. July 2022;170:119\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.027.","DOI":"10.1016\/j.ejca.2022.04.027"},{"key":"15808_CR9","doi-asserted-by":"publisher","unstructured":"Kattan MW, Vickers AJ. Statistical Analysis and Reporting Guidelines for CHEST, Chest, vol. 2020;158(1):S3\u2013S11. https:\/\/doi.org\/10.1016\/j.chest.2019.10.064.","DOI":"10.1016\/j.chest.2019.10.064"},{"key":"15808_CR10","doi-asserted-by":"publisher","unstructured":"Yazdani A, Haghighat S. Determining Prognostic Factors of Disease-Free Survival in Breast Cancer Using Censored Quantile Regression. Breast Cancer Basic Clin Res. Jan. 2022;16:117822342211080. https:\/\/doi.org\/10.1177\/11782234221108058.","DOI":"10.1177\/11782234221108058"},{"key":"15808_CR11","doi-asserted-by":"publisher","unstructured":"Ricci C, et al. Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. Endocr Relat Cancer. May 2020;27(5):275\u201383. https:\/\/doi.org\/10.1530\/ERC-19-0468.","DOI":"10.1530\/ERC-19-0468"},{"key":"15808_CR12","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology - a primer, Am. J. Cancer Res., vol. 2021;11(4):1121\u20131131."},{"key":"15808_CR13","doi-asserted-by":"publisher","unstructured":"Reynoso-Nover\u00f3n N et al. Dec., Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular, J. Glob. Oncol., 2017;3(6):757\u2013764. https:\/\/doi.org\/10.1200\/JGO.2016.007377.","DOI":"10.1200\/JGO.2016.007377"},{"key":"15808_CR14","doi-asserted-by":"publisher","unstructured":"Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. Jan. 2010;11(1):55\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(09)70314-6.","DOI":"10.1016\/S1470-2045(09)70314-6"},{"key":"15808_CR15","doi-asserted-by":"publisher","unstructured":"Cardoso F, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. Aug. 2016;375(8):717\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1602253.","DOI":"10.1056\/NEJMoa1602253"},{"key":"15808_CR16","doi-asserted-by":"publisher","unstructured":"Chan SH, et al. Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas. Sci Rep. Sept. 2017;7(1):10660. https:\/\/doi.org\/10.1038\/s41598-017-10333-x.","DOI":"10.1038\/s41598-017-10333-x"},{"key":"15808_CR17","doi-asserted-by":"publisher","unstructured":"Hu C et al. June., Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer, JAMA, 2018;319(23):2401. https:\/\/doi.org\/10.1001\/jama.2018.6228.","DOI":"10.1001\/jama.2018.6228"},{"key":"15808_CR18","doi-asserted-by":"publisher","unstructured":"Wang YA, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer. Dec. 2018;18(1):315. https:\/\/doi.org\/10.1186\/s12885-018-4229-5.","DOI":"10.1186\/s12885-018-4229-5"},{"key":"15808_CR19","doi-asserted-by":"publisher","unstructured":"Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO\u2013Society of Surgical Oncology Guideline. J Clin Oncol. Feb. 2024;42(5):584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225.","DOI":"10.1200\/JCO.23.02225"},{"key":"15808_CR20","doi-asserted-by":"publisher","unstructured":"Pensabene M, Calabrese A, Von Arx C, Caputo R, De Laurentiis M. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology. Cancer Treat Rev. Apr. 2024;125:102702. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102702.","DOI":"10.1016\/j.ctrv.2024.102702"},{"key":"15808_CR21","doi-asserted-by":"publisher","unstructured":"Bhardwaj PV, Abdou YG. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Curr Oncol Rep. Dec. 2022;24(12):1791\u2013800. https:\/\/doi.org\/10.1007\/s11912-022-01340-x.","DOI":"10.1007\/s11912-022-01340-x"},{"key":"15808_CR22","doi-asserted-by":"publisher","unstructured":"Wan Q, et al. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1\/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer. JAMA Netw Open. Apr. 2021;4(4):e216259. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6259.","DOI":"10.1001\/jamanetworkopen.2021.6259"},{"key":"15808_CR23","doi-asserted-by":"publisher","unstructured":"Lambertini M, et al. Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. NPJ Breast Cancer. Feb. 2021;7(1):16. https:\/\/doi.org\/10.1038\/s41523-021-00224-w.","DOI":"10.1038\/s41523-021-00224-w"},{"key":"15808_CR24","doi-asserted-by":"publisher","unstructured":"Muranen TA, et al. Association of germline variation with the survival of women with BRCA1\/2 pathogenic variants and breast cancer. NPJ Breast Cancer. Sept. 2020;6:44. https:\/\/doi.org\/10.1038\/s41523-020-00185-6.","DOI":"10.1038\/s41523-020-00185-6"},{"key":"15808_CR25","doi-asserted-by":"publisher","unstructured":"Lin Y, et al. Drug repurposing opportunities for breast cancer and seven common subtypes. J Steroid Biochem Mol Biol. Feb. 2025;246:106652. https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106652.","DOI":"10.1016\/j.jsbmb.2024.106652"},{"key":"15808_CR26","doi-asserted-by":"publisher","unstructured":"Lin Y, Wang S, Zhang L, Yang Q. Elucidating the relationship between breast cancer and brain cortical structure: a Mendelian randomization study. Cereb Cortex. Jan. 2024;34(1):bhad498. https:\/\/doi.org\/10.1093\/cercor\/bhad498.","DOI":"10.1093\/cercor\/bhad498"},{"key":"15808_CR27","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez AC, G\u00f3mez-Flores-Ramos L, Villarreal-Garza C, Mohar-Betancourt A. Germline mutations and prognosis in breast cancer: A systematic review, PROSPERO International prospective register of systematic reviews. Accessed: Apr. 16, 2024. Available: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022308746."},{"key":"15808_CR28","doi-asserted-by":"publisher","unstructured":"Pei R et al. Association of BRCA1 K1183R Polymorphism with Survival in BRCA1\/2-Negative Chinese Familial Breast Cancer, Clin. Lab., 2014;60(1):01\/2014 https:\/\/doi.org\/10.7754\/Clin.Lab.2013.121130.","DOI":"10.7754\/Clin.Lab.2013.121130"},{"key":"15808_CR29","doi-asserted-by":"publisher","unstructured":"Milanese J-S, et al. Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients. Npj Precis Oncol. Nov. 2019;3(1):1\u20139. https:\/\/doi.org\/10.1038\/s41698-019-0100-7.","DOI":"10.1038\/s41698-019-0100-7"},{"key":"15808_CR30","doi-asserted-by":"publisher","unstructured":"Yu K-D et al. Sept., Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial, JAMA Oncol., 2020;6(9):1390\u20131396. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2965.","DOI":"10.1001\/jamaoncol.2020.2965"},{"key":"15808_CR31","doi-asserted-by":"publisher","unstructured":"Szklarczyk D et al. Jan., The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest, Nucleic Acids Res., 2023;51(D1):D638\u2013D646. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","DOI":"10.1093\/nar\/gkac1000"},{"key":"15808_CR32","doi-asserted-by":"publisher","unstructured":"Korobeinikova E, et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet. June 2015;16:70. https:\/\/doi.org\/10.1186\/s12863-015-0234-8.","DOI":"10.1186\/s12863-015-0234-8"},{"key":"15808_CR33","doi-asserted-by":"publisher","unstructured":"Murray JL et al. Apr., Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer, Breast Cancer Res. Treat., 2013;138(3):917\u2013924. https:\/\/doi.org\/10.1007\/s10549-013-2445-x.","DOI":"10.1007\/s10549-013-2445-x"},{"key":"15808_CR34","doi-asserted-by":"publisher","unstructured":"Knechtel G et al. Dec., Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer, J. Cancer Res. Clin. Oncol., 2010;136(12):1813\u20131819. https:\/\/doi.org\/10.1007\/s00432-010-0839-2.","DOI":"10.1007\/s00432-010-0839-2"},{"key":"15808_CR35","doi-asserted-by":"publisher","unstructured":"Gerger A, et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. Feb. 2010;119(3):701\u20135. https:\/\/doi.org\/10.1007\/s10549-009-0417-y.","DOI":"10.1007\/s10549-009-0417-y"},{"key":"15808_CR36","doi-asserted-by":"publisher","unstructured":"Zhu Q et al. Mar., UACA locus is associated with breast cancer chemoresistance and survival, Npj Breast Cancer, 2022;8(1):1\u201312. https:\/\/doi.org\/10.1038\/s41523-022-00401-5.","DOI":"10.1038\/s41523-022-00401-5"},{"key":"15808_CR37","doi-asserted-by":"publisher","unstructured":"Hlav\u00e1\u010d V et al. Mar., Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response, Int. J. Mol. Sci., 2021;22(6):2826. https:\/\/doi.org\/10.3390\/ijms22062826.","DOI":"10.3390\/ijms22062826"},{"key":"15808_CR38","doi-asserted-by":"publisher","unstructured":"Morra A, et al. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res BCR. Aug. 2021;23(1):86. https:\/\/doi.org\/10.1186\/s13058-021-01450-7.","DOI":"10.1186\/s13058-021-01450-7"},{"key":"15808_CR39","doi-asserted-by":"publisher","unstructured":"Pamu\u0142a-Pi\u0142at J, T\u0119cza K, Kalinowska-Herok M, Grzybowska E. Genetic 3\u2032UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients. Sci Rep. Mar. 2020;10(1):5736. https:\/\/doi.org\/10.1038\/s41598-020-62662-z.","DOI":"10.1038\/s41598-020-62662-z"},{"issue":"8","key":"15808_CR40","doi-asserted-by":"publisher","first-page":"e0200996","DOI":"10.1371\/journal.pone.0200996","volume":"13","author":"D Cot\u00e9","year":"2018","unstructured":"Cot\u00e9 D, et al. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). PLoS ONE. 2018;13(8):e0200996. https:\/\/doi.org\/10.1371\/journal.pone.0200996.","journal-title":"PLoS ONE"},{"key":"15808_CR41","doi-asserted-by":"publisher","unstructured":"Toomey S et al. Nov., The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer, Oncotarget, 2016;7(46):75518\u201375525. https:\/\/doi.org\/10.18632\/oncotarget.12782.","DOI":"10.18632\/oncotarget.12782"},{"issue":"4","key":"15808_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/1354750X.2016.1141989","volume":"21","author":"R Ugenskien\u0117","year":"2016","unstructured":"Ugenskien\u0117 R, et al. The contribution of SIPA1 and RRP1B germline polymorphisms to breast cancer phenotype, lymph node status and survival in a group of Lithuanian young breast cancer patients. Biomark Biochem Indic Expo Response Susceptibility Chem. 2016;21(4):363\u201370. https:\/\/doi.org\/10.3109\/1354750X.2016.1141989.","journal-title":"Biomark Biochem Indic Expo Response Susceptibility Chem"},{"key":"15808_CR43","doi-asserted-by":"publisher","unstructured":"Jia Y-M, Xie Y-T, Wang Y-J, Han J-Y, Tian X-X, Fang W-G. Association of Genetic Polymorphisms in CDH1 and CTNNB1 with Breast Cancer Susceptibility and Patients\u2019 Prognosis among Chinese Han Women. PLoS ONE. Aug. 2015;10(8):e0135865. https:\/\/doi.org\/10.1371\/journal.pone.0135865.","DOI":"10.1371\/journal.pone.0135865"},{"issue":"7","key":"15808_CR44","doi-asserted-by":"publisher","first-page":"e0133184","DOI":"10.1371\/journal.pone.0133184","volume":"10","author":"D-N Chen","year":"2015","unstructured":"Chen D-N, Song C-G, Yu K-D, Jiang Y-Z, Ye F-G, Shao Z-M. A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. PLoS ONE. 2015;10(7):e0133184. https:\/\/doi.org\/10.1371\/journal.pone.0133184.","journal-title":"PLoS ONE"},{"key":"15808_CR45","doi-asserted-by":"publisher","unstructured":"Seibold P, et al. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer. Dec. 2015;15:978. https:\/\/doi.org\/10.1186\/s12885-015-1957-7.","DOI":"10.1186\/s12885-015-1957-7"},{"key":"15808_CR46","doi-asserted-by":"publisher","unstructured":"Vulsteke C et al. Oct., Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel, Breast Cancer Res. Treat., 2014;147(3):557\u2013570. https:\/\/doi.org\/10.1007\/s10549-014-3105-5.","DOI":"10.1007\/s10549-014-3105-5"},{"key":"15808_CR47","doi-asserted-by":"publisher","unstructured":"Pande M, et al. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat. Sept. 2014;147(2):381\u20137. https:\/\/doi.org\/10.1007\/s10549-014-3081-9.","DOI":"10.1007\/s10549-014-3081-9"},{"key":"15808_CR48","doi-asserted-by":"publisher","unstructured":"Muendlein A et al. Mar., Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer, J. Cancer Res. Clin. Oncol., 2013;139(3):491\u2013498. https:\/\/doi.org\/10.1007\/s00432-012-1355-3.","DOI":"10.1007\/s00432-012-1355-3"},{"key":"15808_CR49","doi-asserted-by":"publisher","unstructured":"Absenger G et al. Nov., A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer, Mol. Carcinog., 2013;52(S1):96\u2013102. https:\/\/doi.org\/10.1002\/mc.22028.","DOI":"10.1002\/mc.22028"},{"key":"15808_CR50","doi-asserted-by":"publisher","unstructured":"Fasching PA et al. Sept., The role of genetic breast cancer susceptibility variants as prognostic factors, Hum. Mol. Genet., 2012;21(17):3926\u20133939. https:\/\/doi.org\/10.1093\/hmg\/dds159.","DOI":"10.1093\/hmg\/dds159"},{"key":"15808_CR51","unstructured":"Maae E et al. Sept., Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer, Anticancer Res., 2012;32(9):3619\u20133627."},{"key":"15808_CR52","doi-asserted-by":"publisher","unstructured":"Yu K-D, Huang A-J, Fan L, Li W-F, Shao Z-M. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res. Jan. 2012;72(2):408\u201319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2998.","DOI":"10.1158\/0008-5472.CAN-11-2998"},{"key":"15808_CR53","doi-asserted-by":"publisher","unstructured":"Chae YS et al. Dec., VARS2 V552V variant as prognostic marker in patients with early breast cancer, Med. Oncol. Northwood Lond. Engl., 2011;28(4):1273\u20131280. https:\/\/doi.org\/10.1007\/s12032-010-9574-4.","DOI":"10.1007\/s12032-010-9574-4"},{"key":"15808_CR54","doi-asserted-by":"publisher","unstructured":"Varadi V et al. Aug., Genetic variation in genes encoding for polymerase \u03b6 subunits associates with breast cancer risk, tumour characteristics and survival, Breast Cancer Res. Treat., 2011;129(1):235\u2013245. https:\/\/doi.org\/10.1007\/s10549-011-1460-z.","DOI":"10.1007\/s10549-011-1460-z"},{"key":"15808_CR55","doi-asserted-by":"publisher","unstructured":"Azzato EM, et al. Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor\u2013Negative Breast Cancer Survival. JNCI J Natl Cancer Inst. May 2010;102(9):650\u201362. https:\/\/doi.org\/10.1093\/jnci\/djq057.","DOI":"10.1093\/jnci\/djq057"},{"key":"15808_CR56","doi-asserted-by":"publisher","unstructured":"Milanese J-S, et al. eTumorMetastasis: A Network-based Algorithm Predicts Clinical Outcomes Using Whole-exome Sequencing Data of Cancer Patients. Genomics Proteom Bioinf. Dec. 2021;19(6):973\u201385. https:\/\/doi.org\/10.1016\/j.gpb.2020.06.009.","DOI":"10.1016\/j.gpb.2020.06.009"},{"key":"15808_CR57","doi-asserted-by":"publisher","unstructured":"Escala-Garcia M, et al. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nat Commun. Jan. 2020;11(1):312. https:\/\/doi.org\/10.1038\/s41467-019-14100-6.","DOI":"10.1038\/s41467-019-14100-6"},{"issue":"6","key":"15808_CR58","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/bcr3076","volume":"13","author":"T Heikkinen","year":"2011","unstructured":"Heikkinen T, et al. Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res BCR. 2011;13(6):R130. https:\/\/doi.org\/10.1186\/bcr3076.","journal-title":"Breast Cancer Res BCR"},{"key":"15808_CR59","doi-asserted-by":"publisher","unstructured":"Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Insulin-like Growth Factor-I Receptor\/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells, Cancer Res., Dec. 2005;65(23):11118\u201311128. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3841.","DOI":"10.1158\/0008-5472.CAN-04-3841"},{"key":"15808_CR60","doi-asserted-by":"publisher","unstructured":"Zhang J, Kale V, Chen M. Gene-Directed Enzyme Prodrug Therapy. AAPS J. Jan. 2015;17(1):102\u201310. https:\/\/doi.org\/10.1208\/s12248-014-9675-7.","DOI":"10.1208\/s12248-014-9675-7"},{"key":"15808_CR61","doi-asserted-by":"publisher","unstructured":"Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer, Toxicol. In Vitro, 2006;20(2):176\u2013186. https:\/\/doi.org\/10.1016\/j.tiv.2005.06.046.","DOI":"10.1016\/j.tiv.2005.06.046"},{"key":"15808_CR62","doi-asserted-by":"publisher","unstructured":"Braybrooke JP, et al. Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Clin Cancer Res. Feb. 2005;11(4):1512\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0155.","DOI":"10.1158\/1078-0432.CCR-04-0155"},{"key":"15808_CR63","doi-asserted-by":"publisher","unstructured":"Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer, Cytokine Growth Factor Rev., 2006;17(5):325\u2013337. https:\/\/doi.org\/10.1016\/j.cytogfr.2006.07.002.","DOI":"10.1016\/j.cytogfr.2006.07.002"},{"key":"15808_CR64","doi-asserted-by":"publisher","unstructured":"Yu L, Li L, Medeiros LJ, Young KH. NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev. Mar. 2017;31(2):77\u201392. https:\/\/doi.org\/10.1016\/j.blre.2016.10.001.","DOI":"10.1016\/j.blre.2016.10.001"},{"key":"15808_CR65","doi-asserted-by":"publisher","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. July 2018;119(2):141\u201352. https:\/\/doi.org\/10.1038\/s41416-018-0127-5.","DOI":"10.1038\/s41416-018-0127-5"},{"key":"15808_CR66","doi-asserted-by":"publisher","unstructured":"Robson M et al. Aug., Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, N. Engl. J. Med., 2017;377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","DOI":"10.1056\/NEJMoa1706450"},{"key":"15808_CR67","doi-asserted-by":"publisher","unstructured":"Tutt ANJ, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer. N Engl J Med. June 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","DOI":"10.1056\/NEJMoa2105215"},{"key":"15808_CR68","doi-asserted-by":"publisher","unstructured":"Litton JK et al. Aug., Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation, N. Engl. J. Med., 2018;379(8):753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa1802905.","DOI":"10.1056\/NEJMoa1802905"},{"key":"15808_CR69","doi-asserted-by":"publisher","unstructured":"Manahan ER et al. Oct., Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons, Ann. Surg. Oncol., 2019;26(10):3025\u20133031 https:\/\/doi.org\/10.1245\/s10434-019-07549-8.","DOI":"10.1245\/s10434-019-07549-8"},{"key":"15808_CR70","doi-asserted-by":"publisher","unstructured":"Konstantinopoulos PA et al. Apr., Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline, J. Clin. Oncol., 2020;38(11):1222\u20131245. https:\/\/doi.org\/10.1200\/JCO.19.02960.","DOI":"10.1200\/JCO.19.02960"},{"key":"15808_CR71","doi-asserted-by":"publisher","unstructured":"Koster R et al. Feb., Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics, Genet. Med., 2024;26(2):101032. https:\/\/doi.org\/10.1016\/j.gim.2023.101032.","DOI":"10.1016\/j.gim.2023.101032"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15808-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:21:18Z","timestamp":1781637678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15808-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15808"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15808-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8006972\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CVG Cynthia Villarreal-Garza has received honoraria from Novartis, Pfizer, Lilly, and MSD Oncology. She has been a consultant or advisor for Novartis, Lilly, MSD Oncology, and Amplity Health. Research funding has been provided to her institution by Pfizer. Additionally, she has received travel support, accommodations, or expense reimbursements from MSD Oncology and Pfizer. The author declares no employment, leadership roles, stock ownership, speaker bureau affiliations, patents, royalties, or other financial interests relevant to this work. The rest of the authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}